GENFIT : Corporate presentation - Investor Events - April 2024

Corporate presentation

A P R I L 5 , 2 0 2 4

Disclaimer

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY.

CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. WHILE GENFIT BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM WHICH IT HAS BEEN OBTAINED ARE RELIABLE, GENFIT HAS NOT INDEPENDENTLY VERIFIED THE ASSUMPTIONS ON WHICH PROJECTIONS OF FUTURE TRENDS AND PERFORMANCE ARE BASED. IT MAKES NO GUARANTEE, EXPRESS OR IMPLIED, AS TO THE ACCURACY AND COMPLETENESS OF SUCH INFORMATION.

This presentation contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about GENFIT's corporate strategy and objectives, the potential of elafibranor to receive marketing authorization in the United States, Europe and United Kingdom for PBC, expected milestone and royalty payments for elafibranor in PBC, Ipsen's expectations regarding global peak sales for elafibranor in PBC, Ipsen's ability to effectively maximize commercialization of elafibranor, the potential scope and size of the market for ACLF, commercial certainty within that market, development plans for our pipeline programs and expected timing for potential regulatory approvals and clinical milestones for our drug candidates, as well as projections regarding our cash runway and sources of funding of our research and development. The use of certain words, including "believe, "potential," "expect" and "will" and similar expressions, is intended to identify forward- looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Main Risks and Uncertainties" of the Company's 2022 Universal Registration Document filed with the AMF on April 18, 2023, which is available on the Company's website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC") including the Company's 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2023 or otherwise made public, by the Company.

In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

2

Towards a new GENFIT

ACLF disease state

GENFIT's approach to ACLF

ACLF market opportunity

Highlights on newsflow

2024 Outlook Following Acceptance of Elafibranor Filings in PBC in U.S./EU

▪ Regulatory filings U.S. and Europe

- <6 months after topline data

▪ Expected launch of elafibranor in the U.S.

- Priority Review granted by U.S. FDA

- FDA PDUFA set to June 10, 2024

▪ Financial implications for GENFIT

- Expected milestones of approx. 89M€ by the end of 2024

▪ PBC market

- $1.5bn by 2030 (source Ipsen Capital Market Day December 7, 2023)

▪ Global annual peak sales of elafibranor

- Expected to exceed >500M$ (source Ipsen

Capital Market Day December 7, 2023)

6

Towards a new GENFIT

ACLF Disease state - PART I

Pr . R . Moreau, MD, Senior Scientist (Outstanding Grade), INSERM

GENFIT's approach to ACLF

ACLF market opportunity

Highlights on newsflow

ACLF Day

December 12, 2023

Acute-on-Chronic Liver Failure

(ACLF)

Richard Moreau, MD, FAASLD,1,2,3

1European Foundation for the Study of Chronic Liver Failure (EF CLIF),

Barcelona, Spain;

2Centre de Recherche sur l'Inflammation (CRI),

INSERM, Université Paris Cité, CNRS, Paris, France;

3Service d'hépatologie, Hôpital Beaujon, APHP, Cichy, France.